酒精对HCV感染患者肝功能和肝纤维化进展的影响

肝脏 ›› 2022, Vol. 27 ›› Issue (9): 1008-1010.

酒精对HCV感染患者肝功能和肝纤维化进展的影响

朱雄林, 杨梅, 冯显红, 李小林, 章革民

430400 湖北武汉市新洲区人民医院感染科(朱雄林,章革民),检验科(冯显红),心内科(李小林);430400 湖北武汉市新洲区妇幼保健院妇产科(杨梅)

收稿日期:2021-12-02 出版日期:2022-09-30 发布日期:2022-10-27
基金资助:
武汉市卫生计生委科研基金项目 (WX17C28)

Effects of alcohol consumption on liver function and liver fibrosis progression of hepatitis C patients

ZHU Xiong-lin¹, YANG Mei², FENG Xian-hong³, Li Xiao-lin⁴, ZHANG Ge-min¹

1. Department of Infectious Diseases, Xinzhou District People's Hospital, Wuhan, Hubei 430400, China;
2. Department of Obstetrics and Gynecology, Xinzhou District Maternal and child health hospital, Wuhan, Hubei 430400, China;
3. Department of laboratory, Xinzhou District Maternal and child health hospital, Wuhan, Hubei 430400, China;
4. Department of Cardiology, Xinzhou District People's Hospital, Wuhan, Hubei 430400, China

Received:2021-12-02 Online:2022-09-30 Published:2022-10-27

摘要/Abstract

摘要： 目的探索酒精不同摄入量对丙型肝炎病毒(HCV)感染患者的肝功能和肝纤维化的影响。方法选取近1年来新洲区人民医院收治的HCV感染患者,且病程在10年以上,根据日酒精摄入量分为轻度酒精摄入(20~50 g/d)组和重度酒精摄入(>50 g/d)组,然后检测患者肝功能和肝纤维化指标。结果轻度酒精摄入组的AST为 (115.12 ± 12.14)U/L,ALT (121.83 ± 11.21) U/L,总胆红素(TBil)(84.95 ± 6.21) μmol/L,γ-谷氨酰转肽酶(γ-GT)(72.31 ± 9.21) U/L,均显著低于重度酒精摄入组患者AST (141.34 ± 12.91) U/L,ALT (145.57 ± 10.23) U/L,TBil (95.43 ± 5.38)μmol/L,γ-GT (85.48 ± 8.24) U/L ,均P<0.05);同时,轻度酒精摄入组肝纤维化指标层粘连蛋白(LN)(162.38 ± 21.34) mg/L,III型前胶原(PC-III) (146.74 ± 23.43)μg/L,IV型胶原(IV-C)(198.57 ± 30.34)μg/L,透明质酸酶(HA)(245.98 ± 35.78) mg/L,也显著低于重度酒精摄入组[LN (185.32 ± 18.52) mg/L, PC-III (174.48 ± 19.74) μg/L、IV-C (231.64 ± 27.45) μg/L和HA (289.74 ± 20.36) mg/L]。结论酒精及其摄入量是HCV感染患者肝功能恶化及肝纤维化进展的重要因素,对HCV感染患者的治疗需考虑酒精摄入量。

关键词: 酒精, 丙型肝炎病毒感染, 肝纤维化, 肝功能

Abstract: Objective To explore the effects of different amount of alcohol consumption on liver function and liver fibrosis progression in hepatitis C patients. Methods Hepatitis C Patients treated in our hospital in recent one year and had disease courses of more than 10 years were selected. They were divided into mild alcohol intake group (20g-50g/d) and severe alcohol intake group (more than 50g/d) according to daily amount of alcohol consumption. Liver function and liver fibrosis indicators were detected and compared in both groups of patients. Results The levels of AST (115.12 ± 12.14 U/L), ALT (121.83 ± 11.21 U/L), total bilirubin (TBil) (84.95 ± 6.21 μmol/L) and gamma-glutamyl transferase (γ-GT) (72.31 ± 9.21 U/L) in mild alcohol intake group were significantly lower than those of AST (141.34 ± 12.91 U/L) and ALT (145.57 ± 10.23 U/L), TBil (95.43 ± 5.38 μmol/L) and γ-GT (85.48 ± 8.24 U/L) levels in severe alcohol intake group (P<0.05). Meanwhile, laminin (LN) (162.38 ± 21.34 mg/L), type III procollagen (PC-III) (146.74 ± 23.43 μg/L), type IV collagen (IV-C) (198.57 ± 30.34 μg/L), Hyaluronidase (HA) (245.98 ± 35.78 mg/L) in mild alcohol intake group were significantly lower than those of LN (185.32 ± 18.52 mg/L), PC-III (174.48 ± 19.74 μg/L), IV-C (231.64 ± 27.45 μg/L) and HA (289.74 ± 20.36 mg/L) in the severe alcohol intake group. Conclusion Alcohol consumption are important factors associate with the deterioration of liver function and the progression of liver fibrosis in hepatitis C patients. The patients should be advised to limit alcohol intake for effectively treating liver disease.

Key words: Alcohol, Hepatitis C virus infection, Liver fibrosis, Liver function

朱雄林, 杨梅, 冯显红, 李小林, 章革民. 酒精对HCV感染患者肝功能和肝纤维化进展的影响[J]. 肝脏, 2022, 27(9): 1008-1010.

ZHU Xiong-lin, YANG Mei, FENG Xian-hong, Li Xiao-lin, ZHANG Ge-min. Effects of alcohol consumption on liver function and liver fibrosis progression of hepatitis C patients[J]. Chinese Hepatolgy, 2022, 27(9): 1008-1010.

参考文献

[1] Ray RB, Ray R. Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship. Hepatology, 2019, 69: 889-900.
[2] Rubin EH. Imaging of brain activity and behavioral disorders. Psychiatr Dev, 1986, 4: 65-76.
[3] Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol J, 2019, 7: 642-650.
[4] Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol, 2017, 14: 397-411.
[5] Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol, 2014, 20: 11033-11053.
[6] Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008, 134: 1655-1669.
[7] Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol, 2004, 1: 98-105.
[8] Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Med Clin (Barc), 2017, 148: 78-85.
[9] Proeschold-Bell RJ, Evon DM, Makarushka C, et al. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. Contemp Clin Trials, 2018, 72: 73-85.
[10] Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology, 1998, 28: 805-809.
[11] Serfaty L. Follow-up of patients with chronic hepatitis C and a sustained viral response. Liver Int, 2016, 36 Suppl 1: 67-71.
[12] El-Serag HB, Kramer J, Duan Z, et al. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat, 2016, 23: 687-696.
[13] Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol, 2014, 61: S58-68.
[14] Sobhanimonfared F, Bamdad T, Roohvand F. Cross talk between alcohol-induced oxidative stress and HCV replication. Arch Microbiol, 2020, 202: 1889-1898.
[15] Khan H, Ullah H, Nabavi SM. Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. Food Chem Toxicol, 2019, 124: 182-191.
[16] Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. Scand J Gastroenterol, 1994, 29: 1039-1043.
[17] Donaldson EF, Harrington PR, O'Rear JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology, 2015, 61: 56-65.
[18] Chan C, Levitsky J. Infection and Alcoholic Liver Disease. Clin Liver Dis, 2016, 20: 595-606.
[19] Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest, 2013, 123: 4121-4130.
[20] Osna NA, Ganesan M, Kharbanda KK. Hepatitis C, innate immunity and alcohol: friends or foes? Biomolecules, 2015, 5: 76-94.